FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Freebird Partners LP		 2. Date of Event Requiring Statement (MM/DD/YYYY)
4/3/2023 

 3. Issuer Name and Ticker or Trading Symbol

Eterna Therapeutics Inc. [ERNA]
(Last)        (First)        (Middle)

2800 POST OAK BLVD, SUITE 2000		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

HOUSTON, TX 77056      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, par value $0.005 per share 272582 D (1) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock Purchase Warrant 6/2/2023 6/2/2028 Common Stock, par value $0.005 per share 424928 $3.28 (2)D (1)(2) 
Explanation of Responses:
(1) This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0005 of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.
(2) Pursuant to that certain Securities Purchase Agreement, as announced in the Issuer's Current Report on Form 8-K filed with the SEC on November 25, 2022, the Company issued that certain Common Stock Purchase Warrant ("Warrant") to Freebird Partners LP on December 2, 2022, in substantially the form as the form of warrant filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 2, 2022. The Warrant becomes exercisable on June 2, 2023, and may be exercised through June 2, 2028, at an exercise price of $3.28 per share of Common Stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Freebird Partners LP
2800 POST OAK BLVD, SUITE 2000
HOUSTON, TX 77056
X

Freebird Investments LLC
2800 POST OAK BLVD, SUITE 2000
HOUSTON, TX 77056
X

HUFF CURTIS W
2800 POST OAK BLVD, SUITE 2000
HOUSTON, TX 77056
X
Signatures
Freebird Partners LP, By: Freebird Investments LLC, its general partner, By: /s/ Curtis W. Huff, Chairman and President4/4/2023
**Signature of Reporting PersonDate

Freebird Investments LLC, By: /s/ Curtis W. Huff, Chairman and President4/4/2023
**Signature of Reporting PersonDate

/s/ Curtis W. Huff4/4/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Brooklyn ImmunoTherapeut....
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Brooklyn ImmunoTherapeut....